Development
Evaxion Biotech A/S
EVAX
$3.13
$0.5521.32%
NASDAQ
| 09/30/2023 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 6.97% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 1.50% | ||||
| Operating Income | -1.50% | ||||
| Income Before Tax | 0.61% | ||||
| Income Tax Expenses | 13.78% | ||||
| Earnings from Continuing Operations | 0.09% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | 0.09% | ||||
| EBIT | -1.50% | ||||
| EBITDA | -0.63% | ||||
| EPS Basic | 0.00% | ||||
| Normalized Basic EPS | 0.53% | ||||
| EPS Diluted | 0.00% | ||||
| Normalized Diluted EPS | 0.53% | ||||
| Average Basic Shares Outstanding | -0.09% | ||||
| Average Diluted Shares Outstanding | -0.11% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||